This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (103)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Pneumonia  • Bacterial Infections  • Alert me on articles by topic

Kenneth A. Freedberg, MD, MSc; Julie A. Scharfstein, MS, ScD; George R. Seage III, DSc, MPH; Elena Losina, MS; Milton C. Weinstein, PhD; Donald E. Craven, MD; A. David Paltiel, PhD

JAMA. 1998;279:130-136.

Context.— Multiple options are now available for prophylaxis of opportunistic infections related to the acquired immunodeficiency syndrome (AIDS). However, because of differences in incidence rates as well as drug efficacy, toxicity, and costs, the role of different types of prophylaxis remains uncertain.

Objective.— To determine the clinical impact, cost, and cost-effectiveness of strategies for preventing opportunistic infections in patients with advanced human immunodeficiency virus (HIV) disease.

Design.— We developed a Markov simulation model to compare different strategies for prophylaxis of Pneumocystis carinii pneumonia (PCP), toxoplasmosis, Mycobacterium avium complex (MAC) infection, fungal infections, and cytomegalovirus (CMV) disease in HIV-infected patients. Data for the model were derived from the Multicenter AIDS Cohort Study, randomized controlled trials, and the national AIDS Cost and Services Utilization Survey.

Main Outcome Measures.— Projected life expectancy, quality-adjusted life expectancy, total lifetime direct medical costs, and cost-effectiveness in dollars per quality-adjusted life-year (QALY) saved.

Results.— For patients with CD4 cell counts of 0.200 to 0.300x10⁹/L (200-300/µL) who receive no prophylaxis, we projected a quality-adjusted life expectancy of 39.08 months and average total lifetime costs of $40288. Prophylaxis for PCP and toxoplasmosis with trimethoprim-sulfamethoxazole for patients with CD4 cell counts of 0.200x10⁹/L (200/µL) or less increased quality-adjusted life expectancy to 42.56 months, implying an incremental cost of $16000 per QALY saved. Prophylaxis for MAC for patients with CD4 cell counts of 0.050x10⁹/L (50/µL) or less produced smaller gains in quality-adjusted life expectancy; incremental cost-effectiveness ratios were $35000 per QALY saved for azithromycin and $74000 per QALY saved for rifabutin. Oral ganciclovir for the prevention of CMV infection was the least cost-effective prophylaxis ($314000 per QALY saved). Results were most sensitive to the risk of developing an opportunistic infection, the impact of opportunistic infection history on long-term survival, and the cost of prophylaxis.

Conclusions.— The cost-effectiveness of prophylaxis against HIV-related opportunistic infections varies widely, but prophylaxis against PCP or toxoplasmosis and against MAC delivers the greatest comparative value. In an era of limited resources, these results can be used to set priorities and explore new alternatives for improving HIV patient care.

From the Clinical Economics Research Unit (Drs Freedberg and Scharfstein), Section of General Internal Medicine and the Clinical AIDS Program (Drs Freedberg and Craven), Department of Medicine and Evans Medical Foundation, Boston Medical Center; the Department of Epidemiology and Biostatistics (Drs Freedberg, Seage, and Craven and Ms Losina), Boston University School of Public Health, Boston University School of Medicine, Boston, Mass; the Departments of Health Policy and Management (Drs Freedberg and Weinstein) and Biostatistics (Drs Scharfstein and Weinstein), Harvard School of Public Health, Boston; and the Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Conn (Dr Paltiel).

RELATED ARTICLE

AIDS Drug Regimens That Are Worth Their Costs
David N. Rose
JAMA. 1998;279(2):160-161.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Optimal Time to Initiate HIV Therapy Under Ordered Health States
Shechter et al.
Operations Research 2008;56:20-33.
ABSTRACT  

A Systematic Review of Cost-Utility Analyses in HIV/AIDS: Implications for Public Policy
Hornberger et al.
Med Decis Making 2007;27:789-821.
ABSTRACT  

Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy
Fang et al.
QJM 2007;100:97-105.
ABSTRACT | FULL TEXT  

Incorporating Quality of Evidence into Decision Analytic Modeling
Braithwaite et al.
ANN INTERN MED 2007;146:133-141.
ABSTRACT | FULL TEXT  

The Impact of New York City's 1975 Fiscal Crisis on the Tuberculosis, HIV, and Homicide Syndemic
Freudenberg et al.
Am. J. Public Health 2006;96:424-434.
ABSTRACT | FULL TEXT  

Optimal Allocation of Testing Dollars: The Example of HIV Counseling, Testing, and Referral
Walensky et al.
Med Decis Making 2005;25:321-329.
ABSTRACT  

A Bayesian Approach to Net Health Benefits: An Illustration and Application to Modeling HIV Prevention
Johnson-Masotti et al.
Med Decis Making 2004;24:634-653.
ABSTRACT  

Normal Values for CD4 and CD8 Lymphocyte Subsets in Healthy Chinese Adults from Shanghai
Jiang et al.
CVI 2004;11:811-813.
ABSTRACT | FULL TEXT  

What Is Known About the Cost-Effectiveness of Health Services for Returning Prisoners?
Howell et al.
JOURNAL OF CORRECTIONAL HEALTH CARE 2004;10:399-436.
ABSTRACT  

Clinical Applications in the Decision Analysis Literature: (Comment on Keefer et al. 2004)
Cantor
Decision Analysis 2004;1:23-25.
ABSTRACT  

Cost-Effectiveness of Interventions to Reduce Vertical HIV Transmission from Pregnant Women Who Have Not Received Prenatal Care
Mrus and Tsevat
Med Decis Making 2004;24:30-39.
ABSTRACT  

Utilities Derived from Visual Analog Scale Scores in Patients with HIV/AIDS
Mrus et al.
Med Decis Making 2003;23:414-421.
ABSTRACT  

Cost-effectiveness Implications of the Timing of Antiretroviral Therapy in HIV-Infected Adults
Schackman et al.
Arch Intern Med 2002;162:2478-2486.
ABSTRACT | FULL TEXT  

Identifying Undiagnosed Human Immunodeficiency Virus: The Yield of Routine, Voluntary Inpatient Testing
Walensky et al.
Arch Intern Med 2002;162:887-892.
ABSTRACT | FULL TEXT  

Prophylaxis for Human Immunodeficiency Virus-Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines
Goldie et al.
Arch Intern Med 2002;162:921-928.
ABSTRACT | FULL TEXT  

Analysis of a Population-Based Pneumocystis carinii Pneumonia Index as an Outcome Measure of Access and Quality of Care for the Treatment of HIV Disease
Arno et al.
Am. J. Public Health 2002;92:395-398.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Earlier Initiation of Antiretroviral Therapy for Uninsured HIV-Infected Adults
Schackman et al.
Am. J. Public Health 2001;91:1456-1463.
ABSTRACT | FULL TEXT  

Development of a Real-Time PCR Assay for Detection of Toxoplasma gondii in Pig and Mouse Tissues
Jauregui et al.
J. Clin. Microbiol. 2001;39:2065-2071.
ABSTRACT | FULL TEXT  

Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy
Sendi et al.
J Antimicrob Chemother 1999;44:811-817.
ABSTRACT | FULL TEXT  

Optimizing Care for Persons with HIV Infection
Hecht et al.
ANN INTERN MED 1999;131:136-143.
ABSTRACT | FULL TEXT  

The Cost Effectiveness of Strategies for the Treatment of Intestinal Parasites in Immigrants
Muennig et al.
NEJM 1999;340:773-779.
ABSTRACT | FULL TEXT  

Cost-effectiveness Analyses of Statistically Ineffective Treatments
Trippoli et al.
JAMA 1998;280:1992-1993.
FULL TEXT  

Gains in Life Expectancy from Medical Interventions -- Standardizing Data on Outcomes
Wright and Weinstein
NEJM 1998;339:380-386.
ABSTRACT | FULL TEXT  

A Monte Carlo Simulation of Advanced HIV Disease: Application to Prevention of CMV Infection
Paltiel et al.
Med Decis Making 1998;18:S93-S105.
ABSTRACT  

Effectiveness of Preventing Opportunistic Infections in HIV Patients
JWatch Infect. Diseases 1998;1998:5-5.
FULL TEXT  

AIDS Drug Regimens That Are Worth Their Costs
Rose
JAMA 1998;279:160-161.
FULL TEXT